drugset / Trial / NCT04169100
Novel Form of Acquired Long QT Syndrome
Phase 4
Unknown
25 enrolled
Narrows Institute for Biomedical Research
VA New York Harbor Healthcare System · collab
NaSingle-groupOpen-labelPrevention
Summary
The goal of this study is to determine whether anti-Ro/SSA antibodies are associated with acquired QT prolongation in subjects with connective tissue disease. The investigators will investigate whether gender or race influence correlation between anti-Ro antibody status and prolonged QT interval and the role of inflammatory cytokines in association with anti-Ro antibodies and QT prolongation. The investigators propose to add an additional objective to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
Timeline
- Start
- 2011-09-28
- Primary completion
- 2024-03-31
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prednisone | Other / unclassified | 20 mg | Oral |